BCLI Earnings

BCLI reported its earnings on 2025-08-14, showcasing a revenue of 0.00 against an estimate of , resulting in a 0% surprise. The EPS was -0.34, surpassing the expected -0.41 by 17.07%. The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following BCLI's earnings announcement on 2025-08-14, the stock price moved by 0% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, BCLI's stock price tends to shift by an average of 0.23% in the 10 days leading up to earnings and 2.15% in the 10 days following, providing insight into potential market.

For , analysts estimate BCLI's annual revenue to reach undefined, while the EPS is projected at -0.33. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between BCLI's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, BCLI's stock price typically moves by 0.23% in the 10 days before its earnings and 2.15% in the 10 days after. For the upcoming earnings, analysts expect an EPS of -0.33 and revenue of undefined.

The company faces significant regulatory and funding challenges, including a downgrade to OTCQB, delaying the Phase IIIb trial and impacting investor confidence. Operational delays and cash flow concerns further exacerbate the situation. Despite some positive clinical data, the uncertainty and lack of clear FDA guidance contribute to a strong negative sentiment, likely leading to a sharp stock price decline.